|
|
|
|
| LEADER |
04046nam a2200361 u 4500 |
| 001 |
EB001839829 |
| 003 |
EBX01000000000000001003818 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Urinary incontinence in women
|h Elektronische Ressource
|b the management of urinary incontinence in women
|c National Collaborating Centre for Women's and Children's Health ; commissioned by the National Institute for Health and Care Excellence
|
| 250 |
|
|
|a Second edition
|
| 260 |
|
|
|a London
|b Royal College of Obstetricians and Gynaecologists
|c 2013, September 2013
|
| 300 |
|
|
|a 1 PDF file (iv, 385 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Transcutaneous Electric Nerve Stimulation / methods
|
| 653 |
|
|
|a Urinary Bladder, Overactive
|
| 653 |
|
|
|a Urinary Incontinence / surgery
|
| 653 |
|
|
|a Muscarinic Antagonists / therapeutic use
|
| 653 |
|
|
|a Urinary Incontinence / drug therapy
|
| 710 |
2 |
|
|a National Collaborating Centre for Women's and Children's Health (Great Britain)
|
| 710 |
2 |
|
|a Royal College of Obstetricians and Gynaecologists (Great Britain)
|
| 710 |
2 |
|
|a National Institute for Health and Care Excellence (Great Britain)
|
| 740 |
0 |
2 |
|a Urinary incontinence
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a NICE clinical guidelines
|
| 500 |
|
|
|a Title from PDF title page. - This guidance is a partial update of National Institute for Health and Care Excellence (NICE) clinical guideline 40 (published October 2006) and will replace it.-- P. 2. - Replacement of: Urinary incontinence / National Collaborating Centre for Women's and Children's Health ; commissioned by the National Institute for Health and Clinical Excellence. London : RCOG Press, 2006
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK247723
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a New and updated recommendations have been included based on evidence of the clinical and cost effectiveness of: Antimuscarinic drugs: darifenacin, darifenacin - extended release, fesoterodine - modified release, oxybutinin, oxybutynin - modified release, oxybutynin - transdermal, oxybutynin - topical gel, propiverine, propiverine - extended release, solifenacin, tolterodine, tolterodine - extended release, trospium, trospium - extended release; Percutaneous sacral nerve stimulation (P-SNS) compared with either no active treatment or placebo; Percutaneous posterior tibial nerve stimulation (P-PTNS) compared with either no active treatment or placebo; Transcutaneous posterior tibial nerve stimulation (T-PTNS) compared with either no active treatment or placebo; Transcutaneous sacral nerve stimulation (T-SNS) compared with either no active treatment or placebo; A comparison of T-SNS,
|
| 520 |
|
|
|a This guidance is a partial update of National Institute for Health and Care Excellence (NICE) clinical guideline 40 (published October 2006) and will replace it.
|
| 520 |
|
|
|a T-PTNS and P-PTNS (if these treatments are found to be effective compared with no treatment or placebo); Botulinum toxin A compared with placebo in women with overactive bladder (OAB) caused by detrusor overactivity; Pharmacological treatment compared with neuromodulation in all women with overactive bladder; Pharmacological treatment compared with neuromodulation and botulinum toxin A in women with OAB caused by detrusor overactivity only; Surgical approaches for mid-urethral procedures in women undergoing their primary surgical tape procedure: retropubic bottom up, retropubic top down, transobturator inside out, transobturator outside in, single incision; Interventions for women for whom the primary tape procedure has failed: conservative management, looking only at: lifestyle interventions, specifically weight loss, fluid management and smoking cessation and physical therapy, specifically pelvic floor muscle training, repeat tape procedure, fascial sling, colposuspension
|